10/02/2021 - General information
Only 30% of researchers in the world are women and about 30% of all students choose higher education in the field of science. In the case of the Hospital del Mar Medical Research Institute, 51% of researchers are women, but there is still a long way to go. Historically, the role of women in the field of science has been left in the background. With exceptions, the work of female scientists has been overlooked, ignored, or attributed to their male peers. This was reported by Matilda Joslyn Gage, the inspirer of the #NoMoreMatildas.campaign. But even today, the role of women in research still needs to be vindicated. IMIM and Hospital del Mar are once again promoting this 2021, marked by the COVID-19 pandemic, the #SheInspiredMe campaign, in which researchers, doctors and nurses explain which women have been their source. of inspiration to engage in research and to move forward. A vindication of female talent that we want to extend to everyone, encouraging you to record your own videos and post your photos using the hashtag #SheInspiredMe.
Més informació "International Day of Women and Girls in Science- February 11"
09/02/2021 - General information
Dr. Bigas has joined as Deputy Director of Preclinical Research at the Josep Carreras Institute, maintaining her relationship with the Hospital del Mar Medical Research Institute (IMIM), where she leads the Stem Cells and Cancer group. The new responsibility that Dr. Bigas assumes will serve to enhance coordination between all groups in the institute that do basic and translational research, seeking synergies between them and optimizing their research, as well as to enhance the existing collaboration between the professionals of our institute and those of the IMIM. In the last ten years, as head of the Stem Cells and Cancer group, she has studied the molecular and physiological processes of stem cells in different tissues, in order to draw similarities with the appearance and progression of cancerous processes. In particular, her research focuses on the study of hematopoietic stem cells, responsible for the formation of blood cells, in order to understand the process of leukemia and develop strategies to fight against this disease.Currently, her research group is working on the identification of epigenetic and gene expression profiles, which allow discovering new therapeutic targets not yet exploited clinically.
20/01/2021 - General information
The Journal of Clinical Investigation has published a review authored by Michelle von Locquenghien, Catalina Rozalén, and Toni Celià-Terrassa, all members of the Cancer Stem Cells & Metastasis Dynamics Lab at the Hospital del Mar Medical Research Institute (IMIM). In the article, they analyse current knowledge on the role of interferons -cytokines (proteins) involved in regulating the function of immune system cells- in the mechanisms that allow tumour cells to develop treatment resistance. The authors explain how the relationship between tumour cells and the immune system evolves as the cancer progresses, causing these cells to acquire systems that enable them to resist attack. They point out that the principal mechanisms used to achieve this are related to interferon signalling. In this respect, they highlight new evidence supporting immunotherapy-mediated immunoediting and show how interferons can impact either treatment response or resistance. All these factors lead the authors to support its potential as a therapeutic strategy in cancer.
Més informació "The role of interferons in tumour cell resistance to immunotherapy"
21/12/2020 - General information
The Codi Risc research project, coordinated by the IMIM Health Services research group and the Neuroscience research group from the Parc Taulí de Sabadell Hospital Consortium, is launching its new website and intranet. Codi Risc is a research project on the prevention of suicidal behaviour based on the Codi Risc Suïcidi (CRS) programme, which was created and implemented in Catalonia in 2014 by the Catalan Government's Department of Health. The purpose of the Codi Risc project is to study the frequency, as well as the epidemiological, clinical, neuropsychological, and biological risk factors involved in suicide attempts and repeated suicide attempts. It also covers the implementation, effectiveness, and costs of the Catalan Government's Codi Risc Suïcidi programme, as well as the development of personalised suicide risk prediction algorithms aimed at preventing suicidal behaviour.
Més informació "Codi RISC research project launches web and intranet"
03/12/2020 - General information
The Catalonian Antidoping Laboratory first obtained the ISO17025 accreditation 20 years ago, in November 2000. The laboratory has been accredited as an anti-doping laboratory since 1985 and is one of 30 laboratories in the world accredited by the World Anti-Doping Agency (WADA). The ISO17025 accreditation of all analytical procedures applied in doping controls was a prerequisite for maintaining doping accreditation from 2001 onwards. ISO17025 is an internationally recognised quality standard designed to guarantee the technical competence of testing laboratories, in other words, to ensure that laboratories deliver accurate, reliable results. In Spain, ISO17025 accreditation is awarded by ENAC (Entidad Nacional de Acreditación), a Spanish Government body.
Més informació "The Catalonian Antidoping Laboratory celebrates 20 years of ISO17025 accreditation."
30/11/2020 - General information
Dr. Dr. María Martínez, head of the neuro-oncology section of the Medical Oncology Service at Hospital del Mar and a researcher in the Cancer Molecular Therapy research group at the Hospital del Mar Medical Research Institute, will chair the Spanish Neuro-Oncology Research Group (Grupo Español de Investigación en Neurooncología; GEINO) for the next two years. Her appointment was confirmed on 27th November at the organisation's assembly, which was held virtually. Dr. Martínez explained that her objective at the head of GEINO is "To maintain and strengthen the execution of clinical trials in neuro-oncology, both for primary central nervous system tumours and brain metastases, and to continue down the same path as the previous chairmanship with regard to the most basic and translational researchers, as well as to build bridges and collaborate with other cooperative groups".
Més informació "Dr. María Martínez, new president of the Spanish Neuro-Oncology Research Group"
27/11/2020 - General information
Research involving doctors and researchers from Hospital del Mar and the Hospital del Mar Medical Research Institute, led by the INCLIVA Health Research Institute at Hospital Clínico in Valencia, directed by Dr. Pilar Eroles, Co-coordinator of the Breast Cancer Biology Research Group, has demonstrated, for the first time, that the under-expression of miR-33b is related to a poor prognosis in patients suffering HER2+, one of the most aggressive breast cancers and associated with a low survival rate.
10/11/2020 - General information
The director of the Neuropsychiatry and Addictions Institute at Hospital del Mar and coordinator of the Mental Health Research Group at the Hospital del Mar Medical Research Institute will be the president of the organisation for the next four years. Up to now, he has been the Vice-president of the society. Dr. Víctor Pérez, Director of the Institute of Neuropsychiatry and Addictions (INAD) at Hospital del Mar, will be the President of the Spanish Society of Biological Psychiatry (Sociedad Española de Psiquiatría Biológica; SEPB) for the next four years. He was elected at the society's Ordinary General Assembly, held virtually on 29 October.
06/11/2020 - General information
Each November, the Movember Foundation encourages men from all over the world to grow a moustache to raise awareness and funds for men's health research. The Health Services Research Group at the Hospital del Mar Medical Research Institute (IMIM) is the Spanish coordinator for an international initiative funded by this foundation since 2017. The project, entitled "TrueNTH Global Registry- Prostate Cancer Outcomes", focuses on men diagnosed with localised prostate cancer and has the overarching aim of significantly improving the quality of care, and to leverage existing infrastructures and relationships to build success in this research area. During the last four years, nine countries have prospectively collected data from patients to create a joint dataset, expected to include information of more than10,000 patients. As part of this international registry, 25 Spanish sites are monitoring almost 700 patients so far.
Més informació "Movember: researching how to improve quality of life after prostate cancer"
05/11/2020 - General information
The ICOD (Improving Cognition in Down Syndrome) project is being coordinated by the Integrated Pharmacology and Systems Neuroscience Research Group, led by Dr. Rafael de la Torre. It will trial a new therapy to treat cognitive deficits in Down Syndrome sufferers. Six institutions from Spain, France and Italy are taking part. A project led by the Hospital del Mar Medical Research Institute (IMIM), has received a six million euro development grant from the European Commission. The Improving Cognition in Down Syndrome (ICOD) project was one of 75 projects selected within the European Union's Horizon 2020 research and innovation programme. Only nine projects coordinated by Catalan organisations will benefit from these grants, in the last year they are being awarded.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
